Volume 2 - Issue 3, May - June 2026

Cell-free biosystems (CFBS) represent a transformative paradigm in pharmaceutical manufacturing, enabling the synthesis of complex therapeutic molecules outside of living cells. By harnessing cell-free expression systems (CFES), in vitro enzymatic cascades, and modular metabolic pathways, CFBS circumvent many intrinsic limitations of conventional cell-based production, including lengthy fermentation cycles, GMO regulatory burdens, and restricted access in low- and middle-income countries (LMICs). This review systematically examines the mechanistic foundations, key enabling technologies, and emerging applications of CFBS across major drug classes — including alkaloids, polyketide antibiotics, terpenoids, biologic peptides, and vaccine antigens. We critically evaluate current bottlenecks such as cofactor regeneration, extract variability, post-translational modification fidelity, and scaleup economics, while surveying cutting-edge solutions including lyophilized on-demand systems, continuous flow microreactors, and AI-driven pathway optimization. We further analyze regulatory considerations and outline a prospective roadmap for CFBS integration into global pharmaceutical supply chains. Our analysis affirms that CFBS, while not a wholesale replacement for traditional manufacturing, constitute a compelling complementary platform — particularly suited to distributed, rapid-response,and point-of-care drug production — with the potential to substantially democratize access to life-saving medicines.

Braimah M. Nusrat, Ikhenemue O. Oseni, Enuma Chukwunweike Henry,"Cell-Free Biosystems for On-Demand Pharmaceutical Synthesis: A Review of a Novel Platform for Accessible Drug Production" International Journal of Advanced Multidisciplinary Research and Educational Development, V2(3): Page(1053-1062) May-June 2026. ISSN: 3107-6513. www.ijamred.com. Published by Scientific and Academic Research Publishing.